TIDMSTX
RNS Number : 2911E
Shield Therapeutics PLC
28 June 2023
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Results of 2023 Annual General Meeting
London, UK, 28 June 2023: Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with a focus on addressing
iron deficiency with its lead product Accrufer(R)/ Feraccru(R)
(ferric maltol), announces the results of the voting for each of
the resolutions as set out in the Notice of Annual General Meeting
2023. The Board reports that resolutions 1 to 10 passed as ordinary
resolutions and resolutions 11 and 12 were passed as special
resolutions, full details are shown below.
The following table shows the votes cast on each resolution:
VOTES % VOTES AGAINST % WITHHELD
FOR VOTES
Resolution 1 119,538,439 98.78% 1,475,717 1.22% 77,639
------------ ------- -------------- ------- ---------
Resolution 2 104,595,075 86.45% 16,390,220 13.55% 106,500
------------ ------- -------------- ------- ---------
Resolution 3 119,472,808 98.75% 1,512,487 1.25% 106,500
------------ ------- -------------- ------- ---------
Resolution 4 118,885,249 98.26% 2,100,046 1.74% 106,500
------------ ------- -------------- ------- ---------
Resolution 5 119,959,907 99.15% 1,025,388 0.85% 106,500
------------ ------- -------------- ------- ---------
Resolution 6 120,578,657 99.66% 407,538 0.34% 105,600
------------ ------- -------------- ------- ---------
Resolution 7 119,046,402 98.40% 1,938,893 1.60% 106,500
------------ ------- -------------- ------- ---------
Resolution 8 120,575,411 99.64% 437,845 0.36% 78,539
------------ ------- -------------- ------- ---------
Resolution 9 119,859,760 99.06% 1,143,185 0.94% 88,850
------------ ------- -------------- ------- ---------
Resolution 10 118,585,474 97.99% 2,433,532 2.01% 72,789
------------ ------- -------------- ------- ---------
Resolution 11 117,131,887 96.78% 3,892,308 3.22% 67,600
------------ ------- -------------- ------- ---------
Resolution 12 116,917,813 96.61% 4,106,382 3.39% 67,600
------------ ------- -------------- ------- ---------
Notes:
1. Number of shares in issue 713,036,342.
2. Details of the votes received on the resolutions are
available on the Company's website:
https://www.shieldtherapeutics.com/corporate-documents/ .
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Oliver Duckworth +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/ George Dollemore/Alice
Lane/Nigel Birks +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR
Lianne Applegarth/Alice Woodings +44 (0)20 7933 8780 or shield@walbrookpr.com
Investor Contact (US Advisor) +1 617 429 3548 or jmullaly@lifesciadvisors.com
LifeSci Advisors, LLC
John Mullaly
About Accrufer(R)/Feraccru(R)
Accrufer(R)/Feraccru(R) (ferric maltol) is a novel, stable,
non-salt based oral therapy for adults with iron deficiency, with
or without anemia. Accrufer(R)/Feraccru(R) has a novel mechanism of
action compared to other oral iron therapies and has been shown to
be an efficacious and well-tolerated therapy in a range of clinical
trials. More information about Accrufer(R)/Feraccru(R), including
the product label, can be found at: www.accrufer.com and
www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company
with a focus on addressing iron deficiency with its lead product
Accrufer(R)/Feraccru(R) (ferric maltol). The Group has launched
Accrufer(R) in the US and Feraccru(R) is commercialized in the UK
and European Union by Norgine B.V., who also have the marketing
rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialization of Accrufer(R) /
Feraccru(R) in China, Hong Kong, Macau and Taiwan, with Korea
Pharma Co., Ltd. in the Republic of Korea, and with KYE
Pharmaceuticals Inc. in Canada.
Accrufer(R)/Feraccru(R) has patent coverage until the
mid-2030s
Accrufer(R)/Feraccru(R) are registered trademarks of the Shield
Group
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGZZGZVVRMGFZM
(END) Dow Jones Newswires
June 28, 2023 12:30 ET (16:30 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2023 to Apr 2024
